STOCK TITAN

STERIS plc (STE) SEC Filings, Aug-Nov 2026

STE NYSE

STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.

The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.

Rhea-AI Summary

On November 4, 2026, STERIS plc (STE), STERIS Corporation, STERIS Limited and STERIS Irish FinCo Unlimited Company entered into a $1,600 million revolving credit facility, replacing the agreement dated October 7, 2024. No borrowings were incurred on the closing date to refinance and replace that agreement. The facility matures November 4, 2031 and permits up to $800 million in additional commitments, subject to customary conditions.

FinCo also entered into a delayed-draw term loan facility of up to $500 million, with STERIS plc, STERIS Corporation and STERIS Limited as guarantors. It cannot be used unless, among other conditions, the Xodus Medical Acquisition is consummated; commitments terminate if the acquisition is validly terminated or the specified outside date occurs. The loan matures five years after the acquisition closing. Quarterly principal payments begin in year two: 1.25% of principal outstanding on the Acquisition Closing Date in years two and three, then 1.875% in years four and five. Both agreements include leverage and minimum interest-coverage covenants; the term loan covenants apply from funding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.50%
Tags
current report
-
Rhea-AI Summary

STERIS plc (STE) reported fiscal 2027 second-quarter revenue of $1,588.6 million, up 9% from $1,460.3 million, with 8% constant-currency organic growth. Net income attributable to shareholders was $213.7 million and diluted EPS was $2.19, versus $191.9 million and $1.94; adjusted diluted EPS was $2.94 versus $2.47. Life Sciences revenue rose 18% to $170.6 million.

For the first six months, operating cash flow was $656.1 million versus $707.8 million and free cash flow was $492.5 million versus $527.7 million. STERIS attributed the declines primarily to a lower working-capital contribution, partly offset by higher net income. A new targeted restructuring plan, primarily in Healthcare, carries approximately $45 million in charges, including $10 million in cash and $35 million in non-cash charges. It is expected to generate approximately $9 million in annualized savings, partly in fiscal 2028 and fully in subsequent fiscal years.

Fiscal 2027 adjusted EPS outlook increased to $11.35–$11.55 from $11.10–$11.30, including approximately $0.18 from year-to-date tariff refunds. Revenue growth outlook remains 7–8% as reported and 6–7% constant-currency organic. Segment outlook is 6–7% for AST, down from 7–8%, and 9–10% for Life Sciences, up from 6–7%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.50%
Tags
current report
-
Rhea-AI Summary

STERIS plc (STE), through its wholly owned subsidiary STERIS Corporation, agreed to acquire all equity interests of Xodus Medical, Inc., a Pennsylvania-based specialty surgical products business, and certain related affiliates for $2.1 billion in cash at closing, subject to customary adjustments. The agreement also provides for additional earnout consideration of up to $150 million based on specified post-closing performance targets in calendar 2028. The acquisition is anticipated to close by December 31, 2026, subject to customary closing conditions, including regulatory approvals, and is expected to be financed primarily with debt.

STERIS and its subsidiary entered into a bridge financing commitment with JPMorgan Chase Bank and Goldman Sachs for up to $2.0 billion in aggregate through a senior unsecured bridge facility, subject to customary conditions. The commitment may be reduced dollar-for-dollar based on net proceeds from permanent financing or asset sales raised before or after closing. Either party may terminate the purchase agreement if the acquisition has not occurred by July 12, 2027; that date may be extended in certain circumstances to January 11, 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
current report
Rhea-AI Summary

STERIS plc CFO Karen L. Burton had 228 ordinary shares withheld for taxes from 783 restricted ordinary shares that vested on October 1, 2026. She held 12,956 ordinary shares directly following the transaction. As of October 2, 2026, 8,499 of her ordinary shares were restricted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
insider
-
Rhea-AI Summary

STERIS plc (STE) director Richard C. Breeden filed a Rule 144 notice for a proposed sale of up to 4,110 ordinary shares through Charles Schwab on the NYSE, with an indicated aggregate market value of $953,114.00, targeted for 08/18/2026. The shares to be sold were acquired from STERIS plc on 08/13/2025 for cash in an “Exercise & Hold” transaction. In the preceding three months, Breeden reported selling 1,481 shares of STERIS plc on 06/02/2026 for $310,285.00.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
other
-
Rhea-AI Summary

STERIS plc director Mohsen Sohi reported several equity transactions. On 2026-08-12, he exercised 4,058 options with a $86.23 exercise price into ordinary shares and sold 4,058 shares at a weighted average price of $235.78 per share, with individual sale prices ranging from $235.73 to $235.89. On 2026-08-10, he received a grant of 1,099 fully vested nonqualified stock options with a $238.91 exercise price and 1,229 fully vested Career Restricted Stock Units, each RSU representing one ordinary share to be delivered six months after his Board service ends.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
insider
Rhea-AI Summary

Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.

STERIS plc director Louis Shapiro received a grant of 1,025 Career Restricted Stock Units, each representing one ordinary share. These units are fully vested immediately and will be settled in ordinary shares six months after the cessation of his Board service, bringing his reported derivative holdings to 2,000 units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
insider
-
Rhea-AI Summary

STERIS plc director Nirav R. Shah reported equity awards consisting of stock options and restricted stock units. On 2026-08-10, he received 1,506 nonqualified stock options to purchase STERIS ordinary shares at an exercise price of $238.91 per share; these options are fully vested and exercisable immediately, and expire on 2036-08-10. On the same date, he also received 512 Career Restricted Stock Units, each representing one ordinary share to be delivered six months after his Board service ends; these RSUs are fully vested immediately. Following the RSU grant, his directly held equity related to these units totals 7,015 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
insider
-
Rhea-AI Summary

Martin Paul Edward reported acquisition or exercise transactions in this Form 4 filing.

STERIS plc director Martin Paul Edward reported compensation-related equity grants. He received 1,506 nonqualified stock options exercisable immediately at $238.91 per share, expiring August 10, 2036, and 512 Career Restricted Stock Units, which are fully vested and will be settled in ordinary shares six months after his Board service ends, bringing his directly held Career RSUs to 5,074.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
insider
Rhea-AI Summary

HOLLAND CHRISTOPHER S reported acquisition or exercise transactions in this Form 4 filing.

STERIS plc director Christopher S. Holland received a grant of 1,025 Career Restricted Stock Units, each representing the right to receive one ordinary share. The units are fully vested immediately and will be settled in ordinary shares six months after his Board service ends. Following this award, he directly holds 5,989 Career Restricted Stock Units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
insider

FAQ

How many STERIS plc (STE) SEC filings are available on StockTitan?

StockTitan tracks 123 SEC filings for STERIS plc (STE), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for STERIS plc (STE)?

The most recent SEC filing for STERIS plc (STE) was filed on November 13, 2026.